Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA

Chinese Journal of Cancer Research

Volumn 25, Issue 6, 2013, Pages 743-748

  Gao, Jianjian ^a   Zhang, Qingyun ^a   Xu, Jianjun ^a   Guo, Lijuan ^a   Li, Xuefeng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer (BC); MicroRNA 21 (miR 21); Real time polymerase chain reaction (real time PCR)

Indexed keywords

CANCER ANTIGEN 153; CARCINOEMBRYONIC ANTIGEN; MICRORNA 16; MICRORNA 21; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELECTROCHEMILUMINESCENCE ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; NUCLEIC ACID AMPLIFICATION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84901641136     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2013.12.04     Document Type: Article

References (27)

1. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70. (Pubitemid 41161233)
2. O'Hara SP, Mott JL, Splinter PL, et al. MicroRNAs: key modulators of post-transcriptional gene expression. Gastroenterology 2009;136:17-25.
3. Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013;12:3262-71.
4. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12. (Pubitemid 46096921)
5. Zheng DL, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-86.
6. Samy N, Ragab HM, El Maksoud NA, et al. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: A short follow-up. Cancer Biomark 2010;6:63-72.
7. Wu ZC, Zhai HS, Yan CL, et al. The value of serum CA15-3, CEA in the early diagnosis of breast cancer. Qiqihar Yi Xue Yuan Xue Bao (in Chinese) 2010;31:1849-50.
8. Song EW. Small molecule RNA for basic research and clinical applications. Beijing: Science and Technology Press, 2007:115-20.
9. Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013;139:223-9.
10. Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008;378:492-504.
11. Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2008;72:397-402. (Pubitemid 351238155)
12. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36. (Pubitemid 351185951)
13. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. (Pubitemid 43357945)
14. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54:1696-704.
15. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61. (Pubitemid 43271657)
16. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-20.
17. Li J, Zhang Y, Zhang W, et al. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Surg Oncol 2013;2013:875078.
18. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.
19. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007;8:R214.
20. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2006;26:2799-803. (Pubitemid 46663837)
21. Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF- 1. Breast Cancer Res Treat 2009;117:131-40.
22. Wang B, Zhang QY. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 2012;138:1659-66.
23. Kumar S, Keerthana R, Pazhanimuthu A, et al. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys.2013;50:210-4.
24. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
25. Huang GL, Zhang XH, Guo GL, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009;21:673-9.
26. Walter BA, Gómez-Macias G, Valera VA, et al. miR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J Cancer 2011;2:67-75.
27. Ozgün A, Karagoz B, Bilgi O, et al. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie 2013;36:115-8.